Ordenar

Buscar

01/09/2024 Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics
Carri n-Barber , I, Monte, TCS, Triginer, L, Garc a-Villanueva, M, Corral, SG, Frutos, AR, Font, J, Galindo-Izquierdo, M, Polo, CDF, Gil, JJF, Moriano, C, Alvarez, ED, Bernab u, P, Vela-Casasempere, P, Cortes-Hern ndez, J, Moreno, SS, Narvaez-Garc a, J, Hern ndez-Mart n, A, Magallares, BP, Garc a, MP, Marras, C, Ramos, C, Gomez-Puerta, JA, Frade-Sosa, B, Fern ndez-Ortiz, A, Garcia-Aparicio, A, Altab s-Gonz lez, I, Hern ndez-Baldiz n, S, Ros-Vilamajo, I, Cirera, SG, Bufort, MG, Sala, L, Mart nez-Barrio, J, de Salazar, JRG, Heredia, S, Torrente-Segarra, V, Brandy-Garcia, AM, Del Amo, NDV, Fito-Manteca, C, Calvo-Alen, J, Pego-Reigosa, JM, R a-Figueroa, I. Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Narvaez-Garc a, J, Dominguez-Alvaro, M, Gal ndez-Agirregoikoa, E, Mendizabal, J, Alcazar, IA, Loricera, J, Garrido-Pu al, N, Casta eda, S, Moya, P, Larena, C, Estrada-Alarc n, P, Galisteo, C, Frutos, AR, Sanjuan, FO, Monte, TCS, Rocha, MV, Ubiaga, CLI, Garcia-Gonzalez, M, Blanco-Alonso, R. Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Fern ndez-Lozano, D, Dom nguez-Alvaro, M, Narvaez-Garc a, J, Garrido-Pu al, N, De Miguel, E, Estrada-Alarc n, P, Hern ndez-Rodr guez, I, Silva-Diaz, M, Belzunegui, JM, Moriano, C, S nchez-Mart n, J, Calvo, I, Aldasoro, V, Alcazar, LA, Loricera, J, Moya, P, Garc a-Villanueva, M, S nchez-Alonso, F, Casta eda, S, Hern ndez, JL, Blanco-Alonso, R. Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment
G mez, MLI, Escudero, PG, L pez, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, R a-Figueroa, I, Su rez, DVF, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Aragu s, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, G mez, IV, Vela-Casasempere, P, Merino, C, Mart nez, MI, Beriain, JAH, Roman, AMR, Calvo-Al n, J. Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Mysler, E, Ignatenko, S, Gordienko, A, Cort s-Hern ndez, J, Agmon-Levin, N, Narongroeknawin, P, Romanowska-Prochnicka, K, Shen, N, Cifersk , H, Kodera, M, Wei, JCC, Leszczynski, P, Lan, JL, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Dai, L, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, Magallares, BP, Sengupta, T, Sips, C, Lau, C, Avrameas, A, Oliver, SJ. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Zhang, YL, Tedeschi, S, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, J, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, D az, C, McCarthy, G, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Tarancon, LC, Stamp, L, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, FitzGerald, J, Dalbeth, N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Effectiveness of Rituximab in IgG4 Related Disease
Lopez-Gutierrez, F, Loricera, J, Hormigos, C, Nu ez, DF, Rodriguez-Laguna, M, Albarado, PM, G mez, MLI, Corominas, H, Silva-D az, M, Arribas, GG, Garcia-Aparicio, A, Urgelles, JF, Casafont-Sole, I, Calabuig, PM, Castaneda, E, Merino, C, Zas, R, Molina-Collada, J, Melero-Gonzalez, RB, Galindez-Agirregoikoa, E, Hern ndez-Mart n, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, V zquez, NM, Gallego-Flores, A, Ra a, NC, Veroz, R, Andres, M, Casta eda, S, Blanco-Alonso, R. Effectiveness of Rituximab in IgG4 Related Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Guerrero, MR, Moriano, C, Santos, CS, Herranz, LS, Garcia, JJ, Barranco, IC, Alvarez, ED. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).